Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Head & Neck 2Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 30Injections 26Pemetrexed 15Interviews as Topic 15tislelizumab 13Specimen Handling 13Carboplatin 13Cisplatin 12Nivolumab 11atezolizumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Bevacizumab 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Platinum 6Paclitaxel 6Leucovorin 6Ipilimumab 6Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CT-P6 × Other solid neoplasm × 90 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡